. 2014 Apr 28;4:4813. doi: 10.1038/srep04813

Table 2. Summary of the different comparative results. (OL = Olanzapine-containing groups; I²%: inconsistency index; P_het: P value for heterogeneity; OR = (CR in OL patient/CR in control group)/(non CR in OL patient/non CR in control group).

Control	Period	Overall or subgroup	Study number (N)	Participant (N)	OR (95%CI)	Z	P	I² (%)	^P_het
Vomiting control	Acute	ALL	5	726	1.95(1.17–3.23)	2.57	0.01	19	0.29
		Chinese	3	441	2.24(0.94–5.33)	1.82	0.07	41	0.18
		All excluding different criteria	4	485	2.39(1.10–5.22)	2.19	0.03	27	0.25
	Delayed	ALL	5	726	2.65(1.36–5.15)	2.88	0.004	67	0.02
		Chinese	3	441	3.11(2.00–4.83)	5.03	0.00001	0	0.42
		All excluding different criteria	4	485	3.24(2.08–5.04)	5.20	0.00001	2	0.38
	Overall	ALL	5	666	4.07(1.59–10.43)	2.92	0.003	82	0.0002
		Chinese	3	381	5.15(2.96–8.96)	5.79	0.00001	21	0.28
		All excluding different criteria	4	425	5.38(3.14–9.20)	6.14	0.00001	14	0.32
Nausea control	Acute	ALL	3	590	1.34(0.77–2.34)	1.03	0.30	31	0.23
		Chinese	2	349	1.80(0.90–3.59)	1.67	0.10	4	0.31
		All excluding different criteria	2	349	1.80(0.90–3.59)	1.67	0.10	4	0.31
	Delayed	ALL	3	590	2.79(1.76–4.43)	4.35	0.0001	38	0.20
		Chinese	2	349	2.54(1.01–6.42)	1.97	0.05	69	0.07
		All excluding different criteria	2	349	2.54(1.01–6.42)	1.97	0.05	69	0.07
	Overall	ALL	2	470	3.40(2.31–5.00)	6.21	0.00001	0	0.35

Table 2. Summary of the different comparative results. (OL = Olanzapine-containing groups; I2%: inconsistency index; Phet: P value for heterogeneity; OR = (CR in OL patient/CR in control group)/(non CR in OL patient/non CR in control group).